Mandate

Vinge represents HealthCap and Wilson Therapeutics AB in private placement

May 22, 2014

Wilson Therapeutics AB has completed a private placement of USD 40,000,000 (SEK 260,000,000) directed to the venture capital firms Abingworth LLP and MVM Life Science Partners LLP and the existing investor HealthCap.

Wilson Therapeutics AB is a life science company focused on the development of drugs for the treatment of Wilson’s Disease, a rare genetic disease that affects approximately 1 in 15,000 people worldwide. The private placement is conducted to finance further product development, clinical trials and commercialisation of the company’s products.

Vinge represented HealthCap and Wilson Therapeutics AB in the private placement and Vinge’s team consisted of partner Jesper Ottergren together with, among others, Kristian Ford and Karin Engström.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025